Healthcare and Pharmaceutical Sector
The healthcare and pharmaceutical sector saw significant regulatory and corporate developments today, including the FDA's accelerated approval of Bristol Myers Squibb's new multiple myeloma treatment ZENBEXUS and an asset acquisition of bankrupt Sangamo Therapeutics by PTC Therapeutics and Eli Lilly for $161 million. On the commercial and earnings front, ten major pharmacy benefit managers agreed to integrate TrumpRx cash prices into their real-time tools, while National Vision raised its full-year operating income outlook following solid second-quarter results.
Ten pharmacy benefit managers and the Pharmaceutical Care Management Association agreed Thursday to display TrumpRx cash prices within their benefit tools. The participating companies, including industry heavyweights CVS Health, OptumRx, and Express Scripts, will list TrumpRx prices alongside plan benefit prices for in-network prescriptions. Patients across commercial, Medicare, and Medicaid plans will be able to view these price comparisons using real-time benefit tools or platform features. CMS Administrator Dr. Mehmet Oz endorsed the move as a way to boost market competition and lower consumer costs. The Trump administration launched the TrumpRx platform earlier this year, building on prior expansions that added hundreds of generic drugs to the portal.
The U.S. Food and Drug Administration granted accelerated approval to Bristol Myers Squibb's ZENBEXUS, or iberdomide, for adult patients with multiple myeloma who have received at least one prior line of therapy. The approval pairs the new pill with daratumumab and hyaluronidase-fihj plus dexamethasone, establishing the first-ever regulatory green light for a cereblon-modulating protein degrader, or CELMoD. Trial data showed the regimen doubled minimal residual disease-negative complete response rates to 41% compared to 21% for the standard comparator arm. The drug carries boxed warnings for embryo-fetal toxicity and thromboembolism, with some patients discontinuing treatment due to adverse reactions. Meanwhile, Bristol Myers Squibb shares traded around $64.66 following the announcement, leaving the stock near consensus price targets.
Biosolution signed a final partnership contract with China Hainan Boao International Hospital on August 13 to supply its autologous chondrocyte therapy, Cartilife, within the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province. The tertiary general hospital holds local sales approval and GMP facilities, enabling immediate procedures and production capacity for 1,000 patients annually. Cartilife is registered locally at 150,000 yuan per session, undercutting the US competing product MACI, which averages over $60,000. CEO Lee Jung-sun stated the partnership marks the beginning of local revenue generation in China, with the company pursuing discussions with other large local hospitals to expand its supply network.